Literature DB >> 29313076

Poly A tail length analysis of in vitro transcribed mRNA by LC-MS.

Michael Beverly1, Caitlin Hagen2, Olga Slack2.   

Abstract

The 3'-polyadenosine (poly A) tail of in vitro transcribed (IVT) mRNA was studied using liquid chromatography coupled to mass spectrometry (LC-MS). Poly A tails were cleaved from the mRNA using ribonuclease T1 followed by isolation with dT magnetic beads. Extracted tails were then analyzed by LC-MS which provided tail length information at single-nucleotide resolution. A 2100-nt mRNA with plasmid-encoded poly A tail lengths of either 27, 64, 100, or 117 nucleotides was used for these studies as enzymatically added poly A tails showed significant length heterogeneity. The number of As observed in the tails closely matched Sanger sequencing results of the DNA template, and even minor plasmid populations with sequence variations were detected. When the plasmid sequence contained a discreet number of poly As in the tail, analysis revealed a distribution that included tails longer than the encoded tail lengths. These observations were consistent with transcriptional slippage of T7 RNAP taking place within a poly A sequence. The type of RNAP did not alter the observed tail distribution, and comparison of T3, T7, and SP6 showed all three RNAPs produced equivalent tail length distributions. The addition of a sequence at the 3' end of the poly A tail did, however, produce narrower tail length distributions which supports a previously described model of slippage where the 3' end can be locked in place by having a G or C after the poly nucleotide region. Graphical abstract Determination of mRNA poly A tail length using magnetic beads and LC-MS.

Entities:  

Keywords:  In vitro transcription; Mass spectrometry; Poly A; Slippage; Tail length; mRNA

Mesh:

Substances:

Year:  2018        PMID: 29313076     DOI: 10.1007/s00216-017-0840-6

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  8 in total

1.  RNA Cleavage Properties of Nucleobase-Specific RNase MC1 and Cusativin Are Determined by the Dinucleotide-Binding Interactions in the Enzyme-Active Site.

Authors:  Priti Thakur; Jowad Atway; Patrick A Limbach; Balasubrahmanyam Addepalli
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

Review 2.  The multifaceted roles of mass spectrometric analysis in nucleic acids drug discovery and development.

Authors:  Thomas Kenderdine; Dan Fabris
Journal:  Mass Spectrom Rev       Date:  2021-12-23       Impact factor: 9.011

Review 3.  Nanomedicine for the Delivery of RNA in Cancer.

Authors:  Michele Ghidini; Sandra G Silva; Jessica Evangelista; Maria Luísa C do Vale; Ammad Ahmad Farooqi; Marina Pinheiro
Journal:  Cancers (Basel)       Date:  2022-05-28       Impact factor: 6.575

4.  Phosphodiester modifications in mRNA poly(A) tail prevent deadenylation without compromising protein expression.

Authors:  Dominika Strzelecka; Miroslaw Smietanski; Pawel J Sikorski; Marcin Warminski; Joanna Kowalska; Jacek Jemielity
Journal:  RNA       Date:  2020-08-20       Impact factor: 4.942

Review 5.  Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain.

Authors:  Zoltán Kis
Journal:  Pharmaceutics       Date:  2022-02-17       Impact factor: 6.321

6.  Novel Mobile Phase to Control Charge States and Metal Adducts in the LC/MS for mRNA Characterization Assays.

Authors:  Steven R Strezsak; Alyssa Jean Pimentel; Ian T Hill; Penny J Beuning; Nicholas J Skizim
Journal:  ACS Omega       Date:  2022-06-17

7.  Human RNase 4 improves mRNA sequence characterization by LC-MS/MS.

Authors:  Eric J Wolf; Sebastian Grünberg; Nan Dai; Tien-Hao Chen; Bijoyita Roy; Erbay Yigit; Ivan R Corrêa
Journal:  Nucleic Acids Res       Date:  2022-10-14       Impact factor: 19.160

Review 8.  mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles.

Authors:  Andreas Ouranidis; Theofanis Vavilis; Evdokia Mandala; Christina Davidopoulou; Eleni Stamoula; Catherine K Markopoulou; Anna Karagianni; Kyriakos Kachrimanis
Journal:  Biomedicines       Date:  2021-12-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.